EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial

Evgeny Pokushalov iD, Andrey Ponomarenko iD, Claire Garcia, Inessa Pak, Evgenya Shrainer iD, Mariya Seryakova, Michael Johnson, Richard Miller

Nutrients · 17.02.2024 · 16 (4) · 557

DOI: 10.3390/nu16040557 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 17.02.2024. Verfasst von Evgeny Pokushalov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for New Medical Technologies, Novosibirsk 630090, Russia. Hauptthemen laut MEDLINE: Inulin, Psyllium, Mannans. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: S.Lab (SOLOWAYS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to determine the impact of a fiber supplement on body weight and composition in individuals with obesity with specific genetic polymorphisms. It involved 112 adults with obesity, each with at least one minor allele in the FTO, LEP, LEPR, or MC4R polymorphism. Participants were randomized to receive either a fiber supplement (glucomannan, inulin, and psyllium) or a placebo for 180 days. The experimental group showed significant reductions in body weight (treatment difference: −4.9%; 95% CI: −6.9% to −2.9%; p < 0.01) and BMI (treatment difference: −1.4 kg/m2; 95% CI: −1.7 to −1.2; p < 0.01) compared to placebo. Further significant decreases in fat mass (treatment difference: −13.0%; 95% CI: −14.4 to −11.7; p < 0.01) and visceral fat rating (treatment difference: −1.3; 95% CI: −1.6 to −1.0; p < 0.01) were noted. Homozygous minor allele carriers experienced greater decreases in body weight (treatment difference: −3.2%; 95% CI: −4.9% to −1.6%; p < 0.01) and BMI (treatment difference: −1.2 kg/m2; 95% CI: −2.0 to −0.4; p < 0.01) compared to heterozygous allele carriers. These carriers also had a more significant reduction in fat mass (treatment difference: −9.8%; 95% CI: −10.6 to −9.1; p < 0.01) and visceral fat rating (treatment difference: −0.9; 95% CI: −1.3 to −0.5; p < 0.01). A high incidence of gastrointestinal events was reported in the experimental group (74.6%), unlike the placebo group, which reported no side effects. Dietary supplementation with glucomannan, inulin, and psyllium effectively promotes weight loss and improves body composition in individuals with obesity, particularly those with specific genetic polymorphisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InulinPsylliumMannansAdultHumansPolymorphism, Single NucleotideObesityBody WeightWeight LossDietary SupplementsBody Mass IndexReceptor, Melanocortin, Type 4Alpha-Ketoglutarate-Dependent Dioxygenase FTO

Stichwörter der Autor:innen

dietary fibersgenetic polymorphismsglucomannaninulinobesitypersonalized nutritionpsylliumweight management

Substanzen

(1-6)-alpha-glucomannanInulinPsylliumMC4R protein, humanReceptor, Melanocortin, Type 4FTO protein, humanAlpha-Ketoglutarate-Dependent Dioxygenase FTOMannans

Autor:innen und Institutionen

  • Center for New Medical Technologies, Novosibirsk 630090, Russia.
  • Scientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA.

ORCID-Profile: Evgeny Pokushalov, Andrey Ponomarenko, Evgenya Shrainer

Förderung

  • S.Lab (SOLOWAYS)

Zitieren

APA

Pokushalov, E., Ponomarenko, A., Garcia, C., Pak, I., Shrainer, E., Seryakova, M., Johnson, M., & Miller, R. (2024). The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, 16(4), 557. https://doi.org/10.3390/nu16040557

Vancouver

Pokushalov E, Ponomarenko A, Garcia C, Pak I, Shrainer E, Seryakova M, et al. The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2024;16(4):557. doi:10.3390/nu16040557

BibTeX
@article{Pokushalov2024,
  author = {Pokushalov, Evgeny and Ponomarenko, Andrey and Garcia, Claire and Pak, Inessa and Shrainer, Evgenya and Seryakova, Mariya and Johnson, Michael and Miller, Richard},
  title = {The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {557},
  doi = {10.3390/nu16040557}
}
Kostenlos starten →